Circulating Immune Complexes of IgA Type in Dermatitis Herpetiformis  by Zone, John J. et al.
0022-202X/80/0075-0I 52$02.00/0 
THE JOURNAL OF I NVESTIGATIVE DERMATOLOGY, 75:152-155, 1980 
Copyright © 1980 by The Willi ams & Wilkins Co. 
Vol. 75, No. 2 
Printed in U.S.A. 
Circulating Immune Complexes of lgA Type in Dermatitis Herpetiformis 
JOHN J_ ZONE, M.D., BERNARD A. LASALLE, B.S., AND THOMAS T. PROVOST, M.D. 
Division of Dermatology, University of Utah College of Medicine (JZ to BL), Salt La.lze City, Utah and Department of Dermatology, Johns 
Hophins College of Medicine (TP) Baltimore, Maryland, U.S.A. 
There is some evidence that dermatitis herpetiformis 
may be mediated by circulating immune complexes. This 
study attempts to define th e antibody class of these 
complexes. All patients studied demonstrated granular 
deposition of IgA in the papillary dermis on direct im-
munofluorescence. Serum immune complexes were de-
tected using the qualitative Raji cell immunofluorescent 
assay, as well as the quantitative immunora diometric 
assay. A group of 25 dermatitis herpetiformis patients 
was found to have higher levels of IgA containing com-
plexes compared to a group of normals (p < .01). Higher 
levels of IgG containing complexes were also noted in 
dermatitis herpetiformis patients at a low level of statis-
tical significance (p < .1). The relationship of these com-
plexes to the pathogenesis of dermatitis herpetiformis is 
yet to be determined. 
Dermatitis herpetiformis (DH) is a chronic, intensely pruritic, 
papulovesicular eruption associated with small bowel changes 
which are similar to those seen in gluten-sensitive enteropathy 
[1]. Cutaneous immunopathology reveals granular deposition 
of IgA in the dermal papillae in the vast majority of the cases 
[2,3]. Alternative complement pathway components h ave also 
been identified in the dermal papillae, in a staining pattern, and 
localization similar to IgA deposition [ 4]. These observations 
suggest that lgA may activate the alternative complement 
pathway, playing a role in the pathogenesis of t he lesions of 
DH. 
The origin of the lgA deposits in the papillary dermis is 
unknown, but the lymphocytic cells producing lgA in the small 
bowel are a likely source. Several workers have attempted to 
identify circulating antibodies or immune complexes which 
mediate this potential relationship between the gut and skin . 
Antireticulin antibodies of lgG type have been identified [5,6]. 
Immune complexes reported by British investigators have also 
been of IgG type [7,8]. These reports of mediators of lgG type 
are of questionable pathophysiologic significance in DH, where 
lgA deposition in the dermis is t he characteristic finding. 
We report the detection of circulating immune complexes of 
IgA type in patients with DH. Complexes were initially detected 
using the Raji cell immunoflu orescent technique and confirmed 
by using th e Raji cell immunoradiometric assay. We have been 
able to demonstrate only minimal elevations of IgG conta ining 
complexes in DH patients as a group, as compared to a group 
of normals using the Raji cell technique. 
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MATERIALS AND METHODS 
Patient Selection. 
Patients selected for this study had clinically typical DH, and dem-
onstrated granular deposition of lgA in the dermal papillary tips in 
perilesional skin. Patients with the histologic findings of DH and with 
negative immunoflu orescence or linear lgA deposition were excluded 
from the study. Only one patient was strictly adhering to a glu ten-free 
diet, and aU but 3 patients were rece iving sulfone therapy. Sera from 
healthy blood donors served as controls. SelecLed sera from patients 
with systemic lup us erythematosus were used as positive controls. Sera 
were collected at room temperature, clotted, a liquoted, and frozen at 
-70°C until tested. 
Direct Im.mun.oflu.orescence Technique 
Perilesional skin biopsies were snap-frozen in liquid nitrogen, 
mounted in liquid t issue embedding medium (O.C.T. Ames) and stored 
at -70°C. Sections, 4 fLm in thickness, were cut in a cryostat and ai.r 
dried. The immunofluorescent s taining of these specimens was per-
formed employing flu orescein conjugated ant i-human lgA, IgG, lgM, 
and C3, as previously described [9]. 
Cultured Lymphoblastoid Cells 
Raji cells (American Type Cell Cul ture) ru-e a lymphoblasto id cell 
line with B cell characteristics derived from a patient with Bw-kitt's 
lymphoma [10]. These cells have surface receptors for Fe fragment of 
IgG, C3b, C3d and possibly other complement components. The affini ty 
of the complement receptor is much greater than that of the lgG 
receptor [11]. The C3 receptors have an in vitro tumover rate (half-
life) of 3-4 h1· [12]. Cells were cul tured in RPMI-1640 (Gibco) a nd 1% 
penicillin-streptomycin (Gibco) in 75 mm2 T flasks (Corning) . Cul tures 
seeded with 2 X 10" cells/cc were harvested after 72 Ill" in cul tw-e and 
used for the assay. All cultures exceeded 85% viabili ty as determined 
by trypan blue exclusion. 
Aggregated Human Globulins 
Human lgG was obtained from Cohn Fraction II, pu t over a DEAE-
52 column, and freed from aggregates by centrifugation at 150,000 g for 
90 min. The upper third of the supernate (7S lgG) was removed and 
the protein concent ration was determined by the Lowrey protein assay. 
T he supernatant human 7S IgG was aliquoted a nd stored at -70°C. 
Human IgG was aggregated by heating the supernate in a water bath 
at 63° for 30 min immediate ly before use. 
Human IgA was obtained from serum of patients with IgA myeloma 
by zinc precipitation method [13,14]. IgA was aggregated by coupling 
with bisdiazotized benzidine (BDB) as previously reported [15]. The 
aggregated IgA was then a liquoted a nd stored at -70°C until used. 
Aggregated immunoglobulins were incubated at 37°C for 30 min with 
an eq ual amount of normal huma n serum dilu ted 1:2 with saline. Serial 
dilutions of these prepru·ed cpmplexes were used to establish a standru·d 
cw·ve. 
A ntisera 
Antisera used in dll·ect immunofluorescence and the Raji cell im-
munofluorescent techniques had flu orescein / protein ratios of 2 mg/gm 
and 2.5 mg/gm for antihuman IgA and antihuman lg:G respectively. 
Antisera used in the Raji cell immunoradiometric assay were l gG 
fractions of whole antisera produced in goats. The antihuma n lgG was 
specific to the Fe fragment of human lgG a nd the antihuman lgA was 
specific to the alpha chain of human l gA. All antisera wei"e pu1·chased 
from Cappel Laboratories a nd determined to be monospecific by gel 
double diffusion a nd immunoelectrophoresis. The IgG antiserum did 
not crossreact with 2,920 fLg of aggregated lgA on gel double diffusion, 
nor did the lgA ant iserum crossreact with 1,600 /lg of aggregated IgG_ 
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Radioiodination of Protein 
Antisera used in the immunoradiometric assay were iodinated with 
r• •s (New England Nucleru·) enzymatically using sephru·ose 4B (Phru·-
macia) bound lactoperoxidase [16). The specific activity was 6.6 X 104 
cpm/!.tg protein. 
Raji Cell Im.munoflu.orescent Technique and Imm.u.noradiom.etric 
A ssay 
T h e 72-hr Haji cell cul tures were washed in 30 cc of RPMI-1640 to 
remove C3 receptor activity released in to the spent media [12]. Raji 
cells 2 X lOG in 50 J.!l of RPMI-1640 were reacted with 30 J.!l of a 1:4 
dilution of the serum to be tested in 1.5 ml centrifuge tubes (Eppendor!), 
and incubated in a shaker bath to maintain suspension at 37°C for 45 
min. The cells were washed 3 times with RPMI-1640, reacted with an 
optimum amount (21-26 J.lg protein) of a 1:2 dilu t ion of either fluores-
cein conjugated antisera for the immunofl uorescent technique, or 1125 
labeled antisera for the immunoradiometric assay, in RPMI-1640 con-
taining 1% human serum albumin (RPMI-1640-HSA) and incubated fo r 
30 min at 4°C in a shaker bath. Subsequently, t he cells were washed 3 
times with RPMI-1640-HSA. Cells from the immunofluorescent tech-
nique were mounted on glass slides and examined under ul traviolet 
light epifluorescent microscopy [17]. The radioactivity in the cell pellets 
in the immunoradiometric assay was determined in a gamma counter 
[18]. Quantitative levels of immune complexes in the serum of patients 
and controls were established fro m the standard curve. 
RESULTS 
Raji Cell Immunofluorescent Technique 
IgA immune complexes were detected in the sera of 6 of 18 
patients with DH using the R aji cell immunofluorescent tech-
nique (Table). Positive samples demonstrated immunofluores-
cent granules on the sw-face of the Raji cells. Negative samples 
showed no cellular fluorescence. Only 1 of the 25 control sub-
jects had detectable fluorescence on the cell surface. This is 
significant, p < 0.05, Chi-square analysis. Interestingly, patients 
in both the positive and negative groups were receiving dapsone. 
Four of 6 posit ive patients were receiving dapsone, and 11 of 12 
negatives were receiving dapsone. T he number of patients off 
treatment (3) is too small to evaluate any effect which dapsone 
therapy may have on IgA immune complex formation. 
IgG immune complexes could not be detected in any of the 
patients when the immunofluorescent technique was used. T he 
IgG Fe receptors on Raji cells will normally bind human lgG; 
consequently, the fluorescent technique using antihuman IgG 
produces some background fluorescence. The subjective nature 
of t his component of the assay made it difficul t to assess the 
presence of small amounts of IgG containing immune com-
plexes. Using the fluorescent technique, no significant differ-
ences in IgG containing complexes could subjectively be deter-
mined between the DH patients and normals. 
Raji Cell lnununoradiometric Technique 
F igures 1 and 2 illustrate the standard cw-ves established 
u sing aggregated IgA and aggregated IgG respectively. Coun ts 
per minute (cpm) are listed on the vertical axis, and micrograms 
of aggregated globulin are listed on the horizontal axis. Individ-
Data from Raji cell inununofluorescent t.echnique 
l gA Complexes DH 
Posit ive 6 
Negative 12 
Total 18 
Chi square = p 0.05 
DH Patients Receiving Dapsone 
4 of 6 Posit ives 
11 of 12 Negatives 
lgG Complexes - none detected 
Controls 
1 
24 
25 
a Comparison of DH patients and norrnal contro ls for the presence of · 
immune complexes, using the Raji cell immunofluorescent .assay. Spec-
imens were tested with monospecific antisera for both IgG and IgA. 
The DH group is subdivided into those receiving and not rece iving 
dapsone. 
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FIG l. Standard cm ve for aggregated IgA: Uptake of 1'25 antihuman 
l gA by Raji cells after incubation with vru·ying concentrations of 
prepru·ed aggregated IgA. 
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FIG 2. Standard curve for aggregated IgG: Uptake ofl 1" 5 antihuman 
IgG by Raj i cells afte r incubation with vru·ying concentrations of 
prepared aggregated lgG. 
ual serum values listed in Fig 3 and 4 aTe interpreted from these 
cmves. The aggregated immunoglobulin concentrations repre-
sent ~arying amoun.ts of total protein added to the Raji cells, 
allowmg for compa.nson of results fi·om day-to-day. The aggre-
gated immunoglobulin concentrations do not necessarily reflect 
the amount of protein bound to Raji cells. The quantitative 
significance of the results is best interpreted in relation to a 
group of normals. 
Figuxe 3 illustrates the comparision of 25 DH patients and 20 
controls for the presence of lgA immune complexes. Micro-
grams of aggregated lgA as a log function are listed on the 
vertical axis for the 2 groups. Values represent mean values of 
samples done in duplicate. The mean for the DH patients was 
809 J.Lg, with a standard deviation (SD) of 435 J.Lg. The mean of 
the 20 controls was 260 ~tg with SD of 227 J.Lg, a significant 
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FIG 3. IgA immune complex levels: Haji cell uptake of 1'25 antihu-
man lgA after incubation (37°C for 45 min) with 30 f!l of a 1:4 dilution 
of serum. The comparison is between normal blood donors and der-
matitis herpetiform is patients. Values of systemic lupus erythematosus 
patients are listed for comparison . 
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FIG 4. IgG immune complex levels: Haji cell uptake of 1'25 antihu-
man lgG after incubation (37°C for 45 min) with 30 f!l of a 1:4 dilution 
of serum. The comparison is between normal blood donors and DH 
patients. Values of systemic lupus erythematosus patients are listed for 
comparison. 
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difference, p < .01, Mann-Whitney rank sum test. Six patients 
previously noted to have immune complexes by the immunoflu-
orescent technique had the highest levels of immune complexes 
detected with the immunoradiometric assay. This confirms, 
quantitatively, a qualitative result from the immunofluorescent 
technique. 
In Fig 3, one can see that the blood donor control group had 
levels of immune complexes ranging up to 730 JJ.g of aggregated 
IgA. It is unlikely that quantitative amounts of aggregated IgA 
are actually this high in normal, DH, or lupus sera. Multiple 
methods of preparation of aggregated lgG have made quanti-
tative levels of IgG immune complexes evaluated by various 
assays difficult to compare. Likewise, the introduction of an 
external standard of aggregated IgA also has its inherent prob-
lems. The values are simply a reflection of the external quan-
titative control introduced with a single batch of prepared 
aggregated IgA. In order to allow further interpretation of the 
significance of the levels of complexes detected in DH patients, 
5 patients with severe lupus erythematosus who had very high 
levels of both IgA and IgG complexes are also represented in 
Fig 3 and 4. 
Figure 4 illustrates the levels of IgG containing complexes 
determined using the radioimmunometric assay. Radiolabeled 
antihuman IgG was used for the detection of IgG containing 
complexes. Twenty-five DH patients and 20 controls were 
tested. In this experiment, the Mann-Whitney rank sum test 
revealed a difference between the test group and the control 
group which was statistically significant only at p < 0.1. The 
mean for the DH sera was 18 JJ.g, with an SD of 18 JJ.g. The 
mean for the control group was 8 JJ.g, with SD of 5 J.l.g. In this 
experiment, slightly higher levels of IgG containing complexes 
were detected in DH patients, but the difference was of border-
line statistical significance. 
DISCUSSION 
Attempts at understanding the pathophysiology of DH have 
failed to uncover a circulating substance which physiologically 
mediates the relationship between the gut and the skin abnor-
malities. Mucosal surfaces in DH produce IgA at increased 
rates [19,20] and greater than 80% of biopsies demonstrate 
granular IgA deposition in the dermal papillae [2,3]. In addition 
to the granular IgA, properdin, C3, C5, and properdin factor B 
are frequently found in the dermal papillae. This suggests that 
IgA is fixing complement by the alternative complement path-
way in DR [ 4]. We feel that the circulating mediator in DR 
most likely to be of importance is either an IgA antibody or an 
IgA immune complex which is fixing complement in vivo by 
the alternative complement pathway. Previous work in ow-
laboratory, using indirect immunofluorescent techniques, has 
failed to detect autoantibodies in the serum. This failure has 
led us to look for circulating immune complexes of the IgA 
type. 
Seah et al, have identified circulating antireticulin antibodies 
in 17-20% of their DR patients. These a1·e bound in skin and 
crossreact with gluten protein [5,6,21]. Howevex, they axe of 
IgG type and thexefore of questionable significance. Cu·culating 
reticulin autoantibodies of IgA class have also recently been 
reported [22]. Menzel has recently demonstrated circulating 
antibodies to wheat gliadin in 5 of his 21 patients. These were 
of IgG, IgA, and IgM type [23]. Fw-ther studies are needed to 
evaluate their significance . 
Immune complexes have been repoxted in 35- 80% of DH 
patients by Mowbray, using Clq and anticomplementary tech-
niques [7]. They felt these were of IgG type on the basis of size. 
Mohammed later reported the finding of cu·culating immune 
complexes in 100% of 59 DH patients when Clq binding, radio-
bioassay, and precipitation with polyethylene glycol were em-
ployed [8]. Both lgG and IgM were found in these complexes, 
but lgA was not identified. Again, the antibody type of the 
complex makes the significance of these findings suspect. 
We have selected the Raji cell method of detecting circulating 
immune complexes because of its dependence on cellular recep-
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tors for the 3rd component of complement. This allows the 
detection of complexes which have activated complement by 
either the alternative or classical complement pathway. In 
addition, the use of monospecific antiserum allows classification 
of antibody type present in these complexes. Using this method, 
we have not been able to demonstrate significant differences in 
levels of IgG containing complexes. We are unable to reconcile 
these observations with those of Mohammed and Mowbray, 
who have reported circulating immune complexes apparently 
of IgG type in the vast majority of their patients. However, Clq 
will bind endotoxin and DNA in addition to IgG and IgM 
jrnrnune complexes. P erhaps, nonspecific binding results were 
due to technical problems in methodology which was not well 
defined in the work of Mohammed and Mowbray. 
We have been able to identify significantly higher levels of 
circulating IgA containing complexes in DH patients as a group, 
compared with normals. IgA containing complexes were very 
rare in our examination of serum from normal individuals, and 
consequently we feel that this finding is likely to be significant. 
Of interest is the recent finding of Massey that gliadin will 
activate complement by the alternative complement pathway 
[24]. This provides an attractive hypothesis for mediation of 
disease activity between the gut and skin. Conceptually, one 
could visualize IgA antibodies reacting with wheat antigens in 
the gut, fixing complement via the alternative complement 
pathway and forming IgA containing inmmne complexes. These 
complexes could then travel to the skin and be responsible for 
the immunofluorescent findings. Crossreaction with cutaneous 
antigens could be responsible for complexes fixing in the dermal 
papillae. Recent descriptions of 3 cases of glomerulonephritis 
associated with DH have given further credence to the possi-
bility that inllTiune complexes play a significant role in DH [25-
27]. Granular deposition of IgA in the glomerulus has been 
identified in one of these patients [27]. Crossreactivity with 
primarily cutaneous antigens may account for the low incidence 
of glomerulonephritis. 
In summary, this study showed that IgA containing immune 
complexes do exist in the sera of patients with DH. The true 
test of the biologic role of these complexes awaits correlation 
with disease activity and identification of the antigen present. 
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